---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-063969"
form_type: "8-K"
ticker: "OKUR"
cik: "0001637715"
company_name: "OnKure Therapeutics, Inc."
filed_at: "2025-05-06T23:59:59+00:00"
generated_at: "2026-05-22T12:23:22.740830+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# OnKure Q1 net loss $15.9M, cash $96.7M; PIKture-01 trial on track for H2 2025 data

## Summary
- Net loss of $15.9M ($1.19 per share) vs $9.5M in Q1 2024; R&D expense rose to $13.0M.
- Cash and cash equivalents of $96.7M expected to fund operations into Q4 2026.
- PIKture-01 Part A monotherapy enrollment closed; mature data expected H2 2025.
- Part B fulvestrant combo dose escalation nearing completion; initial data in H2 2025.
- Pan-mutant PI3Kα development candidate to be announced in Q2 2025.

## SEC filing metadata
- accession: 0000950170-25-063969
- form_type: 8-K
- ticker: OKUR
- cik: 0001637715
- company_name: OnKure Therapeutics, Inc.
- filed_at: 2025-05-06T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1637715/000095017025063969/0000950170-25-063969-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1637715/000095017025063969/okur-20250506.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-063969
- JSON: https://secwatch.observer/filing/0000950170-25-063969.json
- Plain text: https://secwatch.observer/filing/0000950170-25-063969.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.